HALEON PLC
LSE:HLN

Watchlist Manager
HALEON PLC Logo
HALEON PLC
LSE:HLN
Watchlist
Price: 373.8 GBX 0.4%
Market Cap: 33.3B GBX

HALEON PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

HALEON PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
HALEON PLC
LSE:HLN
Cash from Operating Activities
ÂŁ2.3B
CAGR 3-Years
19%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Unilever PLC
LSE:ULVR
Cash from Operating Activities
€9.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PZ Cussons PLC
LSE:PZC
Cash from Operating Activities
ÂŁ23.5m
CAGR 3-Years
-22%
CAGR 5-Years
-26%
CAGR 10-Years
-4%
Science in Sport PLC
LSE:SIS
Cash from Operating Activities
ÂŁ852k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Warpaint London PLC
LSE:W7L
Cash from Operating Activities
ÂŁ16m
CAGR 3-Years
103%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Venture Life Group PLC
LSE:VLG
Cash from Operating Activities
ÂŁ4m
CAGR 3-Years
11%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

HALEON PLC
Glance View

Market Cap
33.6B GBX
Industry
Consumer products

In the bustling world of consumer healthcare, HALEON PLC stands as a luminary figure, emerging with a focused mission: to deliver everyday health with humanity. Spun off from the pharmaceutical giant GlaxoSmithKline, HALEON now charts its independent course, concentrating on the development and distribution of over-the-counter medications, oral health products, and nutritional supplements. Its diverse portfolio includes household names such as Sensodyne, Panadol, and Centrum, demonstrating its wide-reaching impact on consumers’ health routines. These brands are not merely market fixtures; they represent HALEON’s commitment to blending scientific innovation with consumer insights, aiming to enhance well-being across the globe. HALEON’s business model is poised at the intersection of healthcare and retail, thriving through an intricate blend of strategic marketing, global distribution networks, and strong brand equity. By leveraging extensive consumer research data, HALEON aligns its product offerings with the evolving needs and preferences of its audience. The company generates revenue primarily through product sales, employing an omnichannel strategy that ensures product availability across various retail and digital platforms. Its strategic alliances and network with pharmacies, supermarkets, and online marketplaces cement its accessibility and prominence in the market. Additionally, HALEON's stream of revenue is bolstered by its investment in innovation—a key driver that keeps its product lines relevant and competitive in a dynamic healthcare landscape.

HLN Intrinsic Value
360.9 GBX
Overvaluation 3%
Intrinsic Value
Price

See Also

What is HALEON PLC's Cash from Operating Activities?
Cash from Operating Activities
2.3B GBP

Based on the financial report for Dec 31, 2024, HALEON PLC's Cash from Operating Activities amounts to 2.3B GBP.

What is HALEON PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
24%

Over the last year, the Cash from Operating Activities growth was 10%. The average annual Cash from Operating Activities growth rates for HALEON PLC have been 19% over the past three years , 24% over the past five years .

Back to Top